Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Post by LithLoveron Apr 02, 2021 10:09am
322 Views
Post# 32931771

Great financials. Confusing call and roll out

Great financials. Confusing call and roll out

Looking at Q4 the numbers are very good.  They had nearly 3 million in revenue and nearly 7 million in cash.  Tripp has said the last few quarters were on a trajectory so 4-5 million for q1 coming on May 17 probably not out of the question. We are already in Q2 (April-June) so probably expect another 4-5 million if not more.  So from a financial point of view easy to see 8-10 million over the next 6 months and cash in the bank.   Question is what does he do with it.  


The prospectus said a couple million on marketing.  Is that still to come?    If they buy these clinics it's an all share deal so cash is still there.  Why not cash and shares.  Makes me thing he has plans for the cash or at least has enough to last years here. 


Now I think most shareholders were hoping for something similar to EXAS where Mercer or physicians or health care groups would be ordering tests for their patients direct from our site.  Physician groups could order direct and employers and certain groups (fire fighters) could order from the site.   Tripp mention regulator issues so maybe that wasn't doable. So instead he's looking at a series of clinics  ok we get that but why HC and not just partner with a large and more well know group or even large hospital or health care group to start first   Why a less know group to test out the roll out?

What we need clarification on is HC Companies.  Who are they? How many clinics? What's their current patient numbers and reach etc?  Basically what are we buying for 15-23 million shares? And why them?

Tripp talked about this AVRT program
like we all should know it.  What is it?  How do you get in it?  Who can refer to it?  Again how many patients are in it and what's its reach?  

And in general this is what I think Noel wanted to know.   What's the process for the general public. If I live in the US and have the $1500 and want to be tested what do I or my doctor need to do    Same in Canada ?  Do I have to show symptoms of cancer or be sick to get tested?   Can referrals be made to AVRT?   Will mercer be using AVRT ?   How are companies that Tripp said that we wanted to partner with in Covid and all the Intake forms we saw, how do they get Aristotle?  


The excitement for the potential we all saw around Aristotle was that any person who wanted to know if they had cancer could get screened early using Aristotle. So do we all have to sign up to HC and AVRT as the only way to get tested?   And if so what's the process for the average joe and where and how can I do this ?    


Finally how will all this be communicated because if all of us who have been following this company for years and the our analyst for Clarus who has a vested interest are confused imagine all the physicians and patients and covid partner.  What's Mercers role in all this. 


We had great financials and are cashed up.   Tripp did well to pivot into Covid and likely made a good move with this looking at the future of health and his options.   He talks incremental growth but he wasn't clear on the process.  


He needs to clarify this right away so the market understands.  And he needs to spend some cash to market this if he expects adoption.  It was a major shift that many did not see coming    The call was not clear nor long enough to explain hence the sell off   We need more detail and clarification on how he intends to reach the masses here   


 

<< Previous
Bullboard Posts
Next >>